L
Lúcio Lara Santos
Researcher at Instituto Português de Oncologia Francisco Gentil
Publications - 186
Citations - 4992
Lúcio Lara Santos is an academic researcher from Instituto Português de Oncologia Francisco Gentil. The author has contributed to research in topics: Bladder cancer & Cancer. The author has an hindex of 35, co-authored 171 publications receiving 3956 citations. Previous affiliations of Lúcio Lara Santos include University of Porto & Fernando Pessoa University.
Papers
More filters
Journal ArticleDOI
Frequency of TERT promoter mutations in human cancers.
João Vinagre,Ana Margarida Almeida,Ana Margarida Almeida,Helena Pópulo,Rui Batista,Joana Lyra,Joana Lyra,Vasco Pinto,Vasco Pinto,Ricardo Marques Coelho,Ricardo Marques Coelho,Ricardo Celestino,Hugo Prazeres,Luís Lima,Miguel Melo,Adriana Gaspar da Rocha,Adriana Gaspar da Rocha,Ana Preto,Ana Preto,Patrícia Castro,Lígia Castro,Fernando Pardal,José Manuel Lopes,José Manuel Lopes,Lúcio Lara Santos,Rui Manuel Reis,José Cameselle-Teijeiro,Manuel Sobrinho-Simões,Manuel Sobrinho-Simões,Jorge Lima,Jorge Lima,Valdemar Máximo,Valdemar Máximo,Paula Soares,Paula Soares +34 more
TL;DR: The results show that TERT promoter mutations are relatively frequent in specific types of human cancers, where they lead to enhanced expression of telomerase.
Journal ArticleDOI
Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients
João D. Barros-Silva,Dina Leitão,Luís Pedro Afonso,Joana Vieira,Mário Dinis-Ribeiro,Maria Candida Barisson Villares Fragoso,Maria José Bento,Lúcio Lara Santos,Paulo Ademar Avelar Ferreira,S Rêgo,Catarina Brandão,Fátima Carneiro,Carla Lopes,Fernando Schmitt,Manuel R. Teixeira +14 more
TL;DR: It is concluded that ER BB2 status may have clinical significance in subsets of gastric cancer patients, and that further studies are warranted to evaluate whether patients whose gastric carcinomas present ERBB2 amplification/overexpression may benefit from therapy targeting this surface receptor.
Journal ArticleDOI
Protein Glycosylation and Tumor Microenvironment Alterations Driving Cancer Hallmarks.
Andreia F. Peixoto,Marta Relvas-Santos,Rita Azevedo,Lúcio Lara Santos,José Alexandre Ferreira +4 more
TL;DR: Focus is set on the pressing need to include glycans and glycoconjugates in comprehensive panomics models envisaging molecular-based precision medicine capable of improving patient care and the transversal nature of glycans throughout the currently accepted cancer hallmarks.
Journal ArticleDOI
Mechanisms of cisplatin resistance and targeting of cancer stem cells: Adding glycosylation to the equation
José Alexandre Ferreira,Andreia F. Peixoto,Manuel Neves,Cristiana Gaiteiro,Celso A. Reis,Yehuda G. Assaraf,Lúcio Lara Santos +6 more
TL;DR: The main cellular and molecular mechanisms underlying cisplatin resistance and the impact of chemotherapy challenge in CSC selection and clinical outcome are summarized and the growing amount of data supporting a role for protein glycosylation in drug resistance is emphasized.
Journal ArticleDOI
Sialyl Tn-expressing bladder cancer cells induce a tolerogenic phenotype in innate and adaptive immune cells.
Mylène A. Carrascal,Paulo F. Severino,Paulo F. Severino,M. Guadalupe Cabral,M. Guadalupe Cabral,Mariana Silva,José Alexandre Ferreira,Fernando M. Calais,Hermínia Quinto,Cláudia Pen,Dário Ligeiro,Lúcio Lara Santos,Fabio Dall'Olio,Paula A. Videira +13 more
TL;DR: Blockade of STn antigens and ofSTn+ glycoprotein, CD44 and MUC1, in STn+ cancer cells was able to lower the induction of tolerance and DCs become more mature.